Emerging and novel therapies for hepatitis C

Gastroenterology and Hepatology

Volumn 6, Issue 10, 2010, Pages

  Jacobson, Ira M ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACH 1625; ALPHA INTERFERON DERIVATIVE; ALPHA2B INTERFERON; BI 201335; BIOLEX; BMS 790052; BMS 791325; BOCEPREVIR; CYCLOPHILIN INHIBITOR; DANOPREVIR; ERYTHROPOIETIN; GS 9256; LOCTERON; N [[[6 (2 CARBOXY 2,3 DIHYDRO 1H ISOINDOL 4 YL) 2,2 DIMETHYLHEXYL]OXY]CARBONYL] 3 METHYLVALYL 4 HYDROXYPROLYL 1 AMINO N (CYCLOPROPYLSULFONYL) 2 ETHYLCYCLOPROPANECARBOXAMIDE LACTONE; NITAZOXANIDE; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON; PEGYLATED INTERFERON LAMBDA; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG;

ANEMIA; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG MECHANISM; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HEPATITIS C; HUMAN; MYALGIA; NEUROPSYCHIATRIC DISEASE; NEUTROPENIA; NOTE; PROTEIN TARGETING; RASH; SKIN MANIFESTATION; THYROID DISEASE; TREATMENT DURATION;

EID: 78549258124     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. McHutchison JG, Manns MP, Muir AJ, et al; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292-1303.
2. McHutchison JG, Everson GT, Gordon SC, et al; PROVE1 Study Team. Telaprevir with peginterferon and ribaviron for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827-1838.
3. Hézode C, Forestier N, Dusheiko G, et al; PROVE2 Study Team. Telaprevir and peginterferon with or without ribaviron for chronic HCV infection. N Engl J Med. 2009;360:1839-1850.
4. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705-716.